Document:

AMENDMENT
      TO

    EMPLOYMENT
      AGREEMENT

     

    THIS
      AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”)
      is
      made as of September 30, 2005, by and among Cleveland BioLabs, Inc., a
      Delaware corporation (the “Company”),
      and
      Dr. Farrel L. Fort (the “Executive”).
      Capitalized terms not otherwise defined herein shall have the meaning ascribed
      to such terms in the Employment Agreement.

     

    RECITALS

     

    WHEREAS,
      the
      Company and the Executive have entered into that certain Employment Agreement,
      dated as of June 1, 2005 (the “Employment
      Agreement”);
      and

     

    WHEREAS,
      the
      Company and the Executive wish to amend and restate Section 2.3 of the
      Employment Agreement in its entirety;

     

    NOW,
      THEREFORE,
      for
      good and valuable consideration, the receipt and adequacy of which is hereby
      acknowledged, the parties hereto hereby agree as follows:

     

    1.  Section
      2.3.
      Section
      2.3 of the Employment Agreement is hereby amended and restated in its entirety
      to read as follows:

     

    “2.3 Incentive
      Stock

     

    The
      Company shall enter into a stock option agreement with the Executive granting
      the Executive an option to purchase 190,000 shares of the Company’s common stock
      pursuant to the vesting schedule provided for therein.”

     

    2.  No
      Amendment or Waiver.
      The
      execution, delivery and effectiveness of this Amendment shall not constitute
      an
      amendment or waiver of any other provision of the Employment Agreement. The
      terms of the Employment Agreement not affected, modified or changed by this
      Amendment shall remain in full force and effect.

     

    3.  References.
      Each
      reference in the Employment Agreement to “this Agreement”, “hereunder”,
“hereof”, “herein”, or words of like import shall mean and be a reference to the
      Employment Agreement as amended hereby, and each reference to the Employment
      Agreement in any other document, instrument or agreement shall mean and be
      a
      reference to the Employment Agreement as amended hereby.

     

    4.  Counterparts.
      This
      Amendment may be executed in two counterparts, each of which shall be deemed
      an
      original, but both of which together shall constitute one and the same
      instrument. Facsimile signatures shall be accepted as originals. 

     

    [Signature
      Page Follows]

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF,
      the
      undersigned or each of their respective duly authorized officers or
      representatives have set their hands hereunder effective upon the date
      referenced-above. 

     

     

      	 	 	 
	 	THE
              COMPANY:
	 	Cleveland BioLabs, Inc.,
              a
              Delaware corporation
	 
 	 
 	 
 
	 	 	/s/ Michael
              Fonstein
	 	
              

              Name:Michael
                Fonstein

            
	 	Title:CEO

    

    
      	 	 	 
	 	 	 
	 	 	 
	 	THE
              EXECUTIVE:
	 
 	 
 	 
 
	 	 	/s/ Farrel
              L.
              Fort 
	 	
              
Farrel
              L. Fort, Ph.D., MBA, DABTAMENDMENT
      TO

    CONSULTING
      AGREEMENT

     

    THIS
      AMENDMENT TO CONSULTING AGREEMENT (“Amendment”)
      is
      made as of January 23, 2006, by and among Cleveland BioLabs, Inc., a Delaware
      corporation (the “Company”), and
      Dr.
      Andrei Gudkov (the “Consultant”).
      Capitalized terms not otherwise defined herein shall have the meaning ascribed
      to such terms in the Consulting Agreement.

     

    R
      E C I T A L S

     

    WHEREAS, the
      Company and the Consultant have entered into that certain Consulting Agreement,
      dated as of August 1, 2004 (the “Consulting
      Agreement”); and

     

    WHEREAS, the
      Company and the Consultant wish to amend and restate Section 2 in its entirety,
      the first sentence of Section 3 of the Consulting Agreement in its entirety
      and
      Section 4 of the Consulting Agreement as provided below;

     

    NOW,
      THEREFORE, for
      good
      and valuable consideration, the receipt and adequacy of which is hereby
      acknowledged, the parties hereto hereby agree as follows:

     

    1. Section
      2.
      Section
      2 of the Consulting Agreement is hereby amended and restated in its entirety
      to
      read as follows:

     

    “2. Term.
      This
      Agreement shall commence on the date hereof and shall continue until December
      31, 2008 (the “Consultation Period”), unless earlier terminated in accordance
      with the provisions of Section 4.”

     

    2. Section
      3. Section
      3
      of the Consulting Agreement is hereby amended and restated in its entirety
      to
      read as follows:

     

    “3. Compensation.

     

    Company
      will pay to a consultant a monthly fee of $5,833.33 based on a work load of
      approximately 25 hours per month.”

     

    3. Section
      4. The
      sentence of Section 4 which reads “Either party may terminate the Agreement,
      without cause, upon 30 days notice in writing to the other party” is hereby
      deleted and Section 4 of the Consulting Agreement is hereby amended and restated
      in its entirety to read as follows:

     

    “4. Termination.
      The
      Company may terminate the Consultation Period, effective immediately upon
      receipt of written notice, but only if the Consultant (a) breaches or threatens
      to breach any provision of Section 6, (b) engages in any malfeasance,
      misconduct, or conduct likely to cause reputational harm to the Company, (c)
      enters into a relationship with any third party which creates a conflict of
      interest with his Consulting Services for the Company, or (d) dies or becomes
      physically or mentally disabled such that, in the Company’s reasonable judgment,
      he cannot perform the duties contemplated hereunder, and any such termination
      under (a), (b), (c) or (d) shall be deemed “for cause” termination. Following
      termination, the Company shall pay all fees owing for services rendered prior
      to
      the termination date, as such fees become payable.”

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    4. No
      Amendment or Waiver. The
      execution, delivery and effectiveness of this Amendment shall not constitute
      an
      amendment or waiver of any other provision of the Consulting Agreement. The
      terms of the Consulting Agreement not affected, modified or changed by this
      Amendment shall remain in full force and effect.

     

    5. References. Each
      reference in the Consulting Agreement to “this Agreement”, “hereunder”,
“hereof”, “herein”, or words of like import shall mean and be a reference to the
      Consulting Agreement as amended hereby, and each reference to the Consulting
      Agreement in any other document, instrument or agreement shall mean and be
      a
      reference to the Consulting Agreement as amended hereby.

     

    6. Counterparts. This
      Amendment may be executed in two counterparts, each of which shall be deemed
      an
      original, but both of which together shall constitute one and the same
      instrument. Facsimile signatures shall be accepted as originals.

     

    [Signature
      Page Follows]

     

     

     

    
 

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    IN
      WITNESS WHEREOF, the
      undersigned or each of their respective duly authorized officers or
      representatives have set their hands hereunder effective upon the date
      referenced-above.

     

    THE
      COMPANY:

    

    

    Cleveland
      BioLabs,
      Inc.,
      a
      Delaware corporation

    

    

    /s/Michael
      Fonstein                                               

    By: Michael
      Fonstein

    Its: President
      and Chief Executive Officer

    

    

    

    THE
      EXECUTIVE:

    

    

    /s/Andrei
      Gudkov                                                     

    By: Andrei
      GudkovAMENDMENT
      TO

    RESTRICTED
      STOCK AGREEMENT

     

    THIS
      AMENDMENT TO RESTRICTED STOCK AGREEMENT (“Amendment”) is
      made
      as of January 23, 2006, by and among Cleveland BioLabs, Inc., a Delaware
      corporation (the “Company”), and
      Michael Fonstein (the “Executive”). Capitalized
      terms not otherwise defined herein shall have the meaning ascribed to such
      terms
      in the Restricted Stock Agreement.

     

    R
      E C I T A L S

     

    WHEREAS, the
      Company and the Executive have entered into that certain Restricted Stock
      Agreement, dated as of July 5, 2003 (the “Restricted
      Stock Agreement”); and

     

    WHEREAS, the
      Company and the Executive wish to amend and restate the definition of “Qualified
      Public Offering” in its entirety and make certain other changes to the
      Restricted Stock Agreement;

     

    NOW,
      THEREFORE, for
      good
      and valuable consideration, the receipt and adequacy of which is hereby
      acknowledged, the parties hereto hereby agree as follows:

     

    1. Section
      6.
      The
      definition of “Qualified Public Offering” in Section 6 of the Restricted Stock
      Agreement is hereby amended and restated in its entirety to read as
      follows:

     

    “Qualified
      Public Offering”
means
      the sale in an underwritten public offering registered under the Securities
      Act
      of shares of the Company’s Common Stock approved by the Board resulting in net
      proceeds to the Company of no less than $7.5 million.”

     

    2. Section
      7.
      The
      following portion of Section 7 of the Restricted Stock Agreement is hereby
      amended and restated in its entirety to read as follows:

     

    “With
      a
      copy to:

     

    Katten
      Muchin Rosenman

    525
      West
      Monroe Street 

    Chicago,
      Illinois 60661

    Fax: (312) 577-8733

    Tel: (312) 902-5520

    Attn: Ram
      Padmanabhan, Esq.”

     

    3. No
      Amendment or Waiver. The
      execution, delivery and effectiveness of this Amendment shall not constitute
      an
      amendment or waiver of any other provision of the Restricted Stock Agreement.
      The terms of the Restricted Stock Agreement not affected, modified or changed
      by
      this Amendment shall remain in full force and effect.

     

    4. References. Each
      reference in the Restricted Stock Agreement to “this Agreement”, “hereunder”,
“hereof’, “herein”, or words of like import shall mean and be a reference to the
      Restricted Stock Agreement as amended hereby, and each reference to the
      Restricted Stock Agreement in any other document, instrument or agreement shall
      mean and be a reference to the Restricted Stock Agreement as amended
      hereby.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    5. Counterparts. This
      Amendment may be executed in two counterparts, each of which shall be deemed
      an
      original, but both of which together shall constitute one and the same
      instrument. Facsimile signatures shall be accepted as originals.

     

    [Signature
      Page Follows]

     

     

     

    
 

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the
      undersigned or each of their respective duly authorized officers or
      representatives have set their hands hereunder effective upon the date
      referenced-above.

     

    THE
      COMPANY:

    

    

    Cleveland
      BioLabs,
      Inc.,
      a
      Delaware corporation

    

    

    /s/
      Michael
      Fonstein                                                           

    By: Michael
      Fonstein

    Its: President
      and Chief Executive Officer

    

    

    

    THE
      EXECUTIVE:

    

    

    /s/
      Michael
      Fonstein                                                           

    Michael
      Fonstein

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]